parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.03 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in hepatocytes	0.75
chemistry Open Targets	reachable by antibody	0.40
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	4 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 6585

CYP4F11 in dopamine neurons, braak-0.15 (p 0.702) → -0.10 (p 0.799)receipt 6593
CYP4F11 in astrocytes, braak-0.46 (p 0.209) → -0.06 (p 0.877)receipt 6592

receipt 6593: CYP4F11 in dopamine neurons, braak

power: full sample -0.33 (p 0.176, n 18), 95% CI -0.69 to +0.16. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.34 (p 0.161, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.44 (p 0.067, n 18). could be the mix.
skeptic: leave-one-out range -0.50 to -0.26, sign flips 0; without severely affected donors -0.33 (p 0.176, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for CYP4F11 in dopamine neurons.

case closed: nothing better to follow up.

receipt 6592: CYP4F11 in astrocytes, braak

power: full sample -0.24 (p 0.328, n 18), 95% CI -0.64 to +0.25. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.23 (p 0.351, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: -0.23 (p 0.360, n 18). could be the mix.
skeptic: leave-one-out range -0.41 to -0.15, sign flips 0; without severely affected donors -0.24 (p 0.328, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for CYP4F11 in astrocytes.

case closed: nothing better to follow up.

loading the receipts